Quick Answer
Ovid Therapeutics Inc. reported Total Assets of $150.93 million for the year ending 2025.
- Ovid Therapeutics Inc. showed an increase of +63.8% in Total Assets from 2024 to 2025.
- This data is from Ovid Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on March 18, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: $47.20 million | Q2 2017: $108.01 million | Q3 2017: $97.57 million | Q1 2018: $78.67 million | Q2 2018: $68.61 million | Q3 2018: $60.39 million | Q1 2019: $66.66 million | Q2 2019: $54.91 million | Q3 2019: $40.69 million | Q1 2020: $61.72 million | Q2 2020: $45.36 million | Q3 2020: $91.60 million | Q1 2021: $237.46 million | Q2 2021: $218.00 million | Q3 2021: $207.09 million | Q1 2022: $191.10 million | Q2 2022: $177.33 million | Q3 2022: $165.03 million | Q1 2023: $143.37 million | Q2 2023: $136.23 million | Q3 2023: $125.03 million | Q1 2024: $131.61 million | Q2 2024: $118.09 million | Q3 2024: $102.65 million | Q1 2025: $81.65 million | Q2 2025: $77.43 million | Q3 2025: $63.85 million.
- Over the full 10 years of available data (2016 to 2025), Ovid Therapeutics Inc.'s Total Assets has grown by 184.6%.
- Historical annual values: Fiscal year 2025: $150.93 million | Fiscal year 2024: $92.17 million | Fiscal year 2023: $144.03 million | Fiscal year 2022: $155.27 million | Fiscal year 2021: $194.54 million | Fiscal year 2020: $75.93 million | Fiscal year 2019: $80.84 million | Fiscal year 2018: $47.65 million | Fiscal year 2017: $89.46 million | Fiscal year 2016: $53.03 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: